|
시장보고서
상품코드
1832018
의약품 여과 시장 : 시장 규모, 점유율, 동향, 예측 - 제품별, 기술별, 용도별, 사업 규모별, 지역별(2025-2033년)Pharmaceutical Filtration Market Size, Share, Trends and Forecast by Product, Technique, Application, Scale of Operation, and Region, 2025-2033 |
||||||
세계의 의약품 여과 시장 규모는 2024년에 160억 5,000만 달러에 달했습니다. IMARC Group은 향후 2033년에는 723억 6,000만 달러에 이를 전망이며, 2025-2033년 17.30%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측했습니다. 북미는 현재 시장을 독점하고 있으며 2024년에는 45.6% 이상 시장 점유율을 차지했습니다. 이는 바이오 의약품에 대한 수요 증가, 엄격한 규제 기준, 지속적인 기술 진보, 의약품의 안전성에 대한 관심 증가로 인한 것입니다.
의약품 여과 시장은 의약품, 생물 제제 및 백신의 품질에 대한 요구가 증가하고 있기 때문에 확대를 보여줍니다. 의약품 제조업체가 엄격한 품질 및 안전 기준의 달성을 목표로 하는 가운데, 제품의 순도를 높이는 고도의 여과 시스템에 대한 요구가 높아지고 있습니다. 의약품 제제는 오염물질, 미생물 및 미립자를 효율적으로 제거하는 여과를 통해 효과적인 성능과 함께 안전 기준을 달성합니다. 이에 따라 멤브레인 여과, 심층 여과, 무균 여과 등의 최신 여과 기술은 변화하는 산업의 요구 사항에 맞게 여과 성능을 향상시키고 있습니다. 또한 맞춤형 의료 및 생물제제의 복잡한 제조 공정을 수행할 수 있는 특수 여과 시스템에 대한 수요가 계속 증가하고 있습니다.
미국에서는 헬스케어 인프라에 대한 정부 투자 증가와 제약 및 바이오테크놀러지 분야의 확대를 배경으로 의약품 여과 시장이 큰 성장을 이루고 있습니다. 예를 들어, 미국 정부는 2024년 9월, 생명공학 및 헬스케어 분야를 지원하는 인프라 정비를 위해 노스캐롤라이나주에 390만 달러의 EDA 투자를 할 것이라고 발표했습니다. 이 나라는 특히 FDA 기준을 통해 강력한 규제 감독을 유지하고 있으며, 이것이 의약품 제조업체에 고품질의 여과 시스템을 채용시키는 원동력이 되고 있습니다. 게다가 의약품 제조를 위탁제조기관(CMO)에 위탁하는 경향이 강해지고 있으며, 의약품의 안전성과 컴플라이언스에 관한 세계 기준을 충족하는 여과 기술에 대한 수요가 높아지고 있습니다.
제약 및 생명 공학 산업의 지출 증가
제약 회사는 연구 개발, 특히 단백질 정제 및 세포 배양과 같은 공정에서 첨단 여과 기술을 필요로 하는 생명공학에 많은 투자를 하고 있습니다. 예를 들어, 보고서에 따르면 주요 제약 회사는 일반적으로 수익의 20%를 연구 개발에 충당하고 있습니다. 또한 제약회사인 AstraZeneca는 2023년 처방약 수익의 23% 이상을 연구개발에 소비하고 있습니다. 또한, 단일클론항체 및 재조합 단백질을 비롯한 바이오 의약품 증가로 제품의 품질과 수율을 보장하기 위해 특수 여과 방법이 필요합니다. 이러한 요인은 의약품 여과 시장의 성장을 더욱 향상시키고 있습니다.
제네릭 의약품 수요 증가
제네릭 의약품 수요 증가는 의약품 여과 시장의 성장을 가속하는 두드러진 요인 중 하나입니다. 예를 들어, IMARC에 따르면 세계 제약 시장 규모는 2023년 3,671억 달러에 달했습니다. IMARC Group은 향후 시장이 2032년까지 6,280억 달러에 이를 전망이며, 2024-2032년 성장률(CAGR)은 5.96%로 성장할 것으로 예측했습니다. 제네릭 의약품은 세계 수요를 충족시키기 위해 대량으로 제조되므로 품질과 규정 준수를 보장하기 위한 효율적이고 확장 가능한 여과 공정이 필요합니다. 이러한 요인은 의약품 여과 시장 예측에 더 긍정적인 영향을 미칩니다.
만성 질환의 유병률 증가
만성 질환의 유병률이 증가하면 다양한 의약품에 대한 수요가 증가합니다. 4대 비전염성 질환은 2030년까지 세계 사망 원인의 75%를 차지할 것으로 추정됩니다. 암, 당뇨병, 천식, COPD, 관절염 등의 만성 질환에 대처하기 위해 신약이 등장하고 있습니다. 예를 들어, 2023년 12월, AstraZeneca Pharma India는 HER2 양성 유방암 치료에 사용되는 트라스투주맙 델크스테칸(상품명 엔하츠)을 출시했습니다. 신약 출시에는 일반적으로 시장 수요를 충족시키기 위해 생산량의 확대가 필요합니다. 이러한 생산량 증가는 제품의 품질과 규제 준수를 보장하기 위한 여과 기술에 대한 수요 증가와 직결됩니다. 이러한 요인은 의약품 여과 시장 점유율을 더욱 밀어 올리고 있습니다.
The global pharmaceutical filtration market size was valued at USD 16.05 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 72.36 Billion by 2033, exhibiting a CAGR of 17.30% from 2025-2033. North America currently dominates the market, holding a market share of over 45.6% in 2024, due to the escalating demand for biopharmaceuticals, stringent regulatory standards, ongoing technological advancements, and growing focus on drug safety.
The pharmaceutical filtration market shows expansion because of escalating requirements for medicines, biologics, and vaccine quality. As pharmaceutical manufacturers aim to achieve strict quality and safety standards, the requirement for advanced filtration systems for product purity has grown. Drug formulations achieve their safety standards along with effective performance through filtration which efficiently eliminates contaminants, microorganisms, and particulates. In line with this, modern filtration technologies such as membrane filtration, depth filtration, and sterile filtration have advanced filtration performance to match the changing industry requirements. Furthermore, the growing demand for specialized filtration systems that can execute complex production processes of personalized medicine and biologics continues to rise.
In the United States, the pharmaceutical filtration market is experiencing significant growth driven by increasing government investments in healthcare infrastructure and the expanding pharmaceutical and biotech sectors. For instance, in September 2024, U.S. government announced a USD 3.9 million EDA investment in North Carolina for infrastructure improvements supporting biotechnology and healthcare sectors. The country maintains strong regulatory oversight especially through FDA standards which drives drug manufacturers to embrace high-quality filtration systems. Furthermore, the growing trend of outsourcing pharmaceutical manufacturing to contract manufacturing organizations (CMOs) enhances demand for filtration technologies that meet global standards for drug safety and compliance.
Rising Spending in Pharmaceutical and Biotechnological Industries
Pharmaceutical companies are investing heavily in research and development, particularly in biotechnology, which requires advanced filtration technologies for processes such as protein purification and cell culture. For instance, according to reports, large pharmaceutical businesses typically dedicate 20% of their earnings to research and development. Also, AstraZeneca, a pharmaceutical company, spent more than 23% of its prescription drug earnings in 2023 on research and development. Moreover, the rise in biopharmaceuticals, including monoclonal antibodies and recombinant proteins, requires specialized filtration methods to ensure product quality and yield. These factors are further driving the pharmaceutical filtration market growth.
Increasing Demand for Generic Drugs
The increasing demand for generic drugs is one of the prominent factors driving the growth in the pharmaceutical filtration market. For instance, according to IMARC, the global generic drugs market size reached USD 367.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 628.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.96% during 2024-2032. Generic drugs are manufactured in large volumes to meet global demand, necessitating efficient and scalable filtration processes to ensure quality and regulatory compliance. These factors are further positively influencing the pharmaceutical filtration industry forecast.
Growing Prevalence of Chronic Diseases
The increased prevalence of chronic diseases increases the demand for a variety of medications. It is estimated that the four major noncommunicable diseases will be responsible for 75% of worldwide deaths by 2030. New medications are introduced to address chronic conditions, such as cancer, diabetes, asthma, COPD, and arthritis. For instance, in December 2023, AstraZeneca Pharma India launched Trastuzumab Deruxtecan, also known as Enhertu, which is used to treat HER2-positive breast cancer. Each new drug launch typically requires scaled-up production to meet the market demand. This increased manufacturing volume directly correlates with higher demand for filtration technologies to ensure product quality and regulatory compliance. These factors are further contributing to the pharmaceutical filtration market share.
Membrane filters stand as the largest product in 2024, holding around 27.8% of the market. Membrane filters are essential in pharmaceutical manufacturing for processes, such as sterile filtration, virus filtration, and protein purification. They are used in bioprocessing applications for cell culture clarification, concentration, and separation of biomolecules. In research laboratories, they are applied for sample preparation, microbiological analysis, and removing particles among a variety of scientific experiments. For instance, in December 2023, TeraPore Technologies, a nanofiltration membranes company, launched IsoBlock VF product line and IsoBlock PF Syringe Prefilter Device for parvovirus elimination from biopharmaceuticals. The IsoBlock PF Syringe Prefilter Device is an adsorptive membrane-based prefilter that removes undesired high-molecular-weight species from the feed prior to size-based virus removal.
Microfiltration leads the market with around 37.6% of market share in 2024. As per the pharmaceutical filtration market outlook, microfiltration is commonly used for sterile filtration to remove microorganisms and particles from pharmaceutical solutions and suspensions. This process is critical in preparing sterile drug products, such as injectables, ophthalmic solutions, and parenteral nutrition solutions. Moreover, it is used for clarification and particle removal in pharmaceutical manufacturing processes. The increasing demand for biologics and biosimilars further drives its adoption, as these products require stringent contamination control. The rising need for biologics together with biosimilars promotes the growth of microfiltration due to their strict requirements for contamination control.
Final product processing leads the market with around 43.7% of market share in 2024. Pharmaceutical filtration during final product processing remains essential for product safety, efficacy, and quality outcomes in the market. Additionally, pharmaceutical solutions and suspensions require sterile filtration to take out microorganisms and particles for achieving stringent sterility requirements. The procedure of sterile filtration eliminates microbiological contaminants present in end-stage drug products, including vaccines and antibiotics along with ophthalmic solutions and other sterile formulations.
Manufacturing scale leads the market with around 67.8% of market share in 2024. The pharmaceutical industry produces medications at industrial levels to fulfill worldwide medicine needs. This high product volume demands powerful filtration methods that guarantee safe and dependable product quality. In addition, the implementation of safety standards and efficacy requirements by regulatory bodies remains enforced upon pharmaceutical manufacturers for ensuring product safety and purity. The manufacturing volumes of biologics, biosimilars, and complex drug formulations demand innovative filtration technologies as an essential necessity. Besides this, technological improvements in filtration systems boost operational productivity by minimizing contamination hazards and bettering output volumes as well as maintaining adherence to strict industry standards.
In 2024, North America accounted for the largest market share of over 45.6%. The region has a strong presence of biopharmaceutical companies engaged in the production of biologics, vaccines, and biosimilars. For instance, in April 2024, Bavarian Nordic A/S, a fully integrated vaccine company, launched Jynneos, the only FDA-approved mpox vaccine in the United States. This sector requires advanced filtration technologies for processes like sterile filtration, virus filtration, and ultrafiltration/diafiltration (UF/DF). Moreover, continued investments in research and development by pharmaceutical companies and academic institutions fuel innovation in filtration technologies, supporting the market growth.
United States Pharmaceutical Filtration Market Analysis
In 2024, United States accounted for 80.50% of the market share in North America. Pharmaceutical filtration is gaining widespread adoption due to increasing investments in healthcare. For instance, U.S. healthcare companies securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. As governments and private entities inject substantial funding into the healthcare sector, there is a notable shift towards modernizing medical infrastructure and improving treatment options. This surge in investment has led to an expansion of pharmaceutical production facilities, which in turn demands high-quality filtration solutions for drug production and purification processes. The need for sterile and safe drug formulations requires the use of advanced filtration technologies that can meet stringent quality standards. As healthcare systems grow and evolve, pharmaceutical filtration systems are increasingly seen as essential in maintaining the efficiency, safety, and effectiveness of the drug development process, contributing to the overall improvement of public health.
Europe Pharmaceutical Filtration Market Analysis
In Europe, the growing adoption of pharmaceutical filtration is driven by the rising incidence of chronic diseases and the aging population. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. As the elderly population continues to increase, so does the prevalence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases. The need for continuous treatment and management of these conditions has boosted the demand for pharmaceutical products. This, in turn, has led pharmaceutical companies to invest in advanced filtration technologies to ensure the quality and safety of their products. The aging population requires long-term care, driving the need for innovative filtration solutions to support the production of high-quality medicines. With healthcare providers striving to meet the needs of an aging demographic, pharmaceutical filtration has become a critical element in ensuring the efficacy and safety of treatments, improving patient outcomes.
Asia Pacific Pharmaceutical Filtration Market Analysis
The adoption of pharmaceutical filtration has seen a significant rise in response to the growing demand for generic medicines. According to National Informatics Centre (NIC), India is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume. The industry manufactures about 60,000 different generic brands across 60 therapeutic categories. With a rapidly increasing population, more individuals are seeking access to medications, and generic drugs have become a popular alternative to branded drugs due to their affordability. The demand for these medicines has led to a rise in pharmaceutical production, which necessitates the implementation of filtration processes to ensure that the final products are free from contaminants. As the need for high-quality, affordable drugs grows, pharmaceutical companies are investing more in filtration technologies to maintain the safety, purity, and compliance of the medications they produce, meeting the growing healthcare needs of the population.
Latin America Pharmaceutical Filtration Market Analysis
The growing adoption of pharmaceutical filtration in Latin America is attributed to the expanding private healthcare sector. According to International Trade Administration, Brazil is the largest healthcare market in Latin America with 7,191 hospitals, 62% are private. With increasing investments in private healthcare infrastructure, more facilities are being established to cater to the growing demand for quality medical services. The shift towards privatization has led to improvements in healthcare services, with a focus on adopting advanced technologies such as filtration systems. These innovations play a crucial role in enhancing the quality of medicines and ensuring that pharmaceutical products meet international standards. As the private sector grows, pharmaceutical manufacturers are adopting filtration systems to meet stricter regulatory standards and improve product safety, driving the increased use of these technologies in the region.
Middle East and Africa Pharmaceutical Filtration Market Analysis
In the Middle East and Africa, the growing adoption of pharmaceutical filtration is driven by the expansion of healthcare facilities. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. With governments and private sector entities investing heavily in healthcare infrastructure, the need for advanced pharmaceutical filtration technologies has risen. These investments are aimed at improving the quality of healthcare services, which includes the production of medicines that adhere to international safety and quality standards. As healthcare facilities expand, pharmaceutical companies are incorporating filtration solutions to meet these standards and improve product safety. The development of healthcare infrastructure in the region is expected to continue driving the demand for pharmaceutical filtration systems, ensuring the availability of safe and effective treatments for the population.
The pharmaceutical filtration market remains competitive because companies focus on enhancing their technological capabilities while ensuring high product quality and following strict regulatory requirements. Moreover, businesses dedicate research investments for developing cutting-edge filtration systems that include membrane filters, sterile filtration, and depth filtration to serve the expanding requirements of drug producing companies alongside biologics producers and vaccine developers. For instance, in October 2024, Asahi Kasei Medical launched the Planova(TM) FG1, a high-flux virus removal filter. It enables time-saving filtration operations while achieving superior virus removal rates and harmonizing with common cleaning procedures which enhances the productivity of pharmaceutical manufacturing. The market demand for high-quality biologic and pharmaceutical products drives competitor focus on offering reliable filtration technologies at cost-effective prices and efficient solutions. In addition, the pharmaceutical sector shows market consolidation due to partnerships and acquisitions which help companies enhance their global pharmaceutical operations through expanded product offerings.